Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:KNTE

Kinnate Biopharma (KNTE) Stock Price, News & Analysis

Kinnate Biopharma logo

About Kinnate Biopharma Stock (NASDAQ:KNTE)

Key Stats

Today's Range
$2.64
$2.68
50-Day Range
$2.45
$2.66
52-Week Range
$1.04
$7.18
Volume
2.81 million shs
Average Volume
418,678 shs
Market Capitalization
$125.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.30
Consensus Rating
Hold

Company Overview

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Kinnate Biopharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
27th Percentile Overall Score

KNTE MarketRank™: 

Kinnate Biopharma scored higher than 27% of companies evaluated by MarketBeat, and ranked 830th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kinnate Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kinnate Biopharma has received no research coverage in the past 90 days.

  • Read more about Kinnate Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Kinnate Biopharma are expected to grow in the coming year, from ($2.51) to ($1.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kinnate Biopharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kinnate Biopharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kinnate Biopharma has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for KNTE.
  • Dividend Yield

    Kinnate Biopharma does not currently pay a dividend.

  • Dividend Growth

    Kinnate Biopharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for KNTE.
  • Search Interest

    2 people have searched for KNTE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Kinnate Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    41.70% of the stock of Kinnate Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    80.89% of the stock of Kinnate Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Kinnate Biopharma's insider trading history.
Receive KNTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.

KNTE Stock News Headlines

Kinetic Engineering Ltd (KNTE)
KNTE Kinnate Biopharma Inc.
Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
See More Headlines

KNTE Stock Analysis - Frequently Asked Questions

Kinnate Biopharma Inc. (NASDAQ:KNTE) announced its quarterly earnings results on Thursday, May, 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.73).

Kinnate Biopharma (KNTE) raised $170 million in an initial public offering (IPO) on Thursday, December 3rd 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kinnate Biopharma investors own include NVIDIA (NVDA), Alibaba Group (BABA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Meta Platforms (META), Canopy Growth (CGC) and DraftKings (DKNG).

Company Calendar

Last Earnings
5/11/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:KNTE
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.30
High Stock Price Target
$2.59
Low Stock Price Target
$2.00
Potential Upside/Downside
-13.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-116,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.06 per share

Miscellaneous

Free Float
27,532,000
Market Cap
$125.13 million
Optionable
Optionable
Beta
1.38
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:KNTE) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners